Unilever won't top $68B bid for GSK consumer healthcare unit
Unilever, the maker of Vaseline skin care products and Dove soap, says it won’t increase a 50 billion-pound ($68.2 billion) offer for GlaxoSmithKline’s consumer healthcare unit that was rejected last week
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Unilever the maker of Vaseline skin care products and Dove soap, says it won’t increase a 50 billion-pound ($68.2 billion) offer for GlaxoSmithKline’s consumer healthcare unit that was rejected last week.
London-based GSK said Saturday that the bid “fundamentally undervalued” the unit. The offer, which included 41.7 billion pounds in cash and Unilever shares valued at 8.3 billion pounds, was the latest of three unsolicited approaches from Unilever, GSK said in a statement.
Unilever responded late Wednesday, saying it wouldn’t increase the bid.
“We note the recently shared financial assumptions from the current owners of GSK Consumer Healthcare and have determined that it does not change our view on fundamental value,” London-based Unilever said in a statement.
After rejecting the Unilever offer, GSK said it remains focused on plans to spin off the consumer unit into a new independent company by the middle of this year. GSK Consumer Healthcare, which makes Sensodyne toothpaste, Advil pain relievers and Centrum vitamins, was formed by the merger of GSK’s consumer business with those of Novartis and Pfizer, which still holds a stake in the unit.
GSK Consumer Healthcare accounts for less than 30% of the parent company’s total revenue, with the rest generated by pharmaceuticals and vaccines.
Shares of GSK rose as much as 5% on Monday after reports of the Unilever bid. The stock has declined over the past two days, dropping 2% to 1,666.4 pence on Wednesday in London trading.